Lupus Nephritis: When Lupus Attacks the Kidneys

When lupus targets the kidneys, the condition is called lupus nephritis. It is one of the most serious complications of systemic lupus erythematosus — the full name of the condition most people simply call lupus. Lupus nephritis lupus attacks kidneys by depositing harmful immune complexes — clumps of antibodies and the proteins they target — directly inside the kidney’s filtering structures. As a result, the filters become inflamed, damaged, and progressively less able to clean the blood.

Lupus nephritis affects roughly 50% of all people diagnosed with lupus at some point in their lives. Furthermore, it is one of the leading causes of kidney failure in young adults — particularly young women — worldwide. However, early diagnosis and modern targeted treatment can prevent the worst outcomes and preserve kidney function for decades. Understanding how lupus attacks the kidneys and what that means for treatment is essential for every person living with lupus.

Quick Answer

Lupus nephritis occurs when lupus — a systemic autoimmune disease — deposits immune complexes inside the kidney’s filtering units, causing inflammation and damage. It affects roughly half of all people with lupus and is a leading cause of kidney failure in young adults. Early diagnosis and aggressive treatment significantly improve long-term kidney outcomes.

How Lupus Attacks the Kidneys

Immune Complexes and Glomerular Damage

In lupus, the immune system produces large amounts of autoantibodies — antibodies that target the body’s own proteins, particularly DNA and nucleoproteins released from damaged cells. These autoantibodies bind to their targets and form immune complexes. Normally, the body clears these complexes quickly. However, in lupus, this clearance system fails. Consequently, immune complexes accumulate in the blood and deposit in the kidneys — particularly inside the glomeruli, the kidney’s tiny filtering units.

Once deposited, these immune complexes activate the complement system — a group of immune proteins that normally help destroy bacteria. In the kidneys, however, complement activation triggers intense local inflammation. White blood cells flood into the glomerular tissue. The delicate capillary walls of the glomerulus become damaged. As a result, the filter begins to leak — allowing blood, protein, and cellular debris to escape into the urine.

The Progressive Damage Cycle

If the immune attack continues unchecked, the initial inflammation gives way to fibrosis — permanent scarring of kidney tissue. Scarred nephrons — the kidney’s individual filtering units — cannot regenerate or recover function. Therefore, each episode of uncontrolled lupus nephritis activity destroys a portion of the kidney’s filtering capacity permanently.

Over time, repeated flares of lupus nephritis accumulate enough scarring to cause chronic kidney disease and eventually kidney failure. Consequently, controlling lupus nephritis activity as early and as completely as possible is the most critical factor in protecting long-term kidney function. For more detail on how kidney function declines over time, see our article on chronic kidney disease stages, symptoms, and how to slow the decline.

Classes of Lupus Nephritis

Understanding the Classification System

Lupus nephritis is not a single uniform disease. It presents in several distinct patterns of kidney injury, classified by kidney biopsy findings. The WHO and International Society of Nephrology and Renal Pathology Society classification system divides lupus nephritis into six classes — numbered I through VI — based on which structures inside the kidney are affected and how severely.

Understanding the class of lupus nephritis is essential because each class carries a different prognosis and requires a different treatment approach. Furthermore, a patient’s class can change over time — either progressing to a more severe form or improving with treatment.

Classes I and II — Minimal and Mild Disease

Class I lupus nephritis involves minimal changes visible only under electron microscopy. The kidneys function normally and patients typically have no kidney symptoms. Class II involves mild deposits around the glomerular support structures — called the mesangium — with only minimal proteinuria. Neither class I nor class II requires immunosuppressive kidney treatment. However, regular monitoring remains important because the disease can progress to a more severe class over time.

Classes III and IV — Active and Serious Disease

Class III — called focal lupus nephritis — affects less than half the glomeruli. Class IV — called diffuse lupus nephritis — affects more than half the glomeruli. Class IV is the most common and most serious form of lupus nephritis. Both classes cause significant glomerular inflammation, heavy proteinuria, blood in the urine, rising blood pressure, and declining kidney function.

Classes III and IV require aggressive immunosuppressive treatment to prevent irreversible kidney damage. Furthermore, class IV carries the highest risk of progression to kidney failure without effective treatment. Consequently, a diagnosis of class III or IV lupus nephritis triggers immediate specialist nephrology and rheumatology management.

Classes V and VI

Class V — called membranous lupus nephritis — produces immune deposits along the outer surface of the glomerular membrane, causing heavy protein leakage into the urine. It produces a predominantly nephrotic picture — similar in appearance to primary membranous nephropathy. For more on membranous kidney disease and its protein loss pattern, see our article on membranous nephropathy autoimmune kidney disease and proteinuria.

Class VI represents advanced chronic scarring with more than 90% of glomeruli irreversibly damaged. At this stage, the kidneys can no longer recover meaningful function. Consequently, treatment at class VI focuses on preparing for kidney replacement therapy rather than attempting to reverse kidney disease.

Symptoms of Lupus Nephritis

Kidney-Specific Symptoms

Lupus nephritis lupus attacks kidneys often silently in the early stages. Many patients have no kidney symptoms at all when lupus nephritis first develops. Consequently, regular urine and blood monitoring in all patients with lupus is essential to detect kidney involvement before symptoms appear.

When symptoms do develop, they reflect the pattern of glomerular damage. Blood in the urine — haematuria — may be visible as red or brown-coloured urine, or detectable only on urine testing. Heavy protein in the urine causes foamy or frothy urine — a symptom patients often describe as persistent bubbles in the toilet bowl that do not clear. For a detailed explanation of what protein in the urine signals about kidney damage, see our article on nephrotic syndrome and what protein in the urine actually tells you.

Swelling — particularly around the eyes, legs, and ankles — develops as protein loss causes fluid to leak out of blood vessels into surrounding tissues. High blood pressure develops as the inflamed kidneys retain salt and water. Moreover, reduced urine output signals worsening kidney function and requires urgent medical assessment.

Systemic Lupus Symptoms

Lupus nephritis rarely occurs in isolation. Most patients also experience the wider symptoms of systemic lupus — including the characteristic butterfly-shaped rash across the cheeks and nose, joint pain and swelling, persistent fatigue, hair loss, mouth ulcers, and sensitivity to sunlight. Furthermore, lupus can also affect the heart, lungs, and brain simultaneously — making it a complex multi-system condition requiring coordinated specialist care across multiple disciplines.

A flare of lupus activity — in which overall disease activity increases — commonly precedes or accompanies a flare of lupus nephritis. Consequently, any patient with lupus who notices worsening systemic symptoms alongside new urinary changes should seek prompt medical review.

How Doctors Diagnose Lupus Nephritis

Blood and Urine Tests

Diagnosing lupus nephritis lupus attacks kidneys begins with urine and blood tests. Urine dipstick testing reveals protein and blood. Urine microscopy — examining the urine under a microscope — looks for red blood cell casts, which are clusters of red blood cells trapped in protein that form inside the kidney tubules. Their presence confirms that the bleeding and inflammation originate within the kidneys rather than the bladder or ureters. For a detailed explanation of this important finding, see our article on nephritic syndrome and blood in the urine.

Blood tests measure serum creatinine and eGFR to quantify kidney function. Anti-dsDNA antibody levels — antibodies against double-stranded DNA — are a key marker of lupus activity. Rising anti-dsDNA levels and falling complement levels — particularly C3 and C4 — strongly suggest active lupus nephritis and prompt urgent further assessment. In addition, a full blood count, clotting studies, antiphospholipid antibodies, and renal function panel complete the initial workup.

Kidney Biopsy

Kidney biopsy is essential for all patients with suspected active lupus nephritis. It identifies the class of lupus nephritis, assesses the degree of active inflammation versus chronic scarring, and guides treatment decisions with precision that blood and urine tests alone cannot achieve.

The biopsy provides two important scores — an activity index reflecting reversible inflammation and a chronicity index reflecting permanent scarring. Furthermore, these scores directly influence treatment intensity. A high activity index with low chronicity suggests that aggressive immunosuppression can still rescue significant kidney function. In contrast, high chronicity with low activity suggests that the damage is largely irreversible and that aggressive immunosuppression carries more risk than benefit. Consequently, the biopsy guides not just which treatment to use but also how aggressively to use it.

Treatment of Lupus Nephritis

Induction Therapy

Treatment of lupus nephritis lupus attacks kidneys follows a two-phase approach — induction and maintenance. Induction therapy aims to rapidly suppress the immune attack, reduce inflammation, and achieve remission as quickly as possible. It is the most intensive phase of treatment and typically lasts three to six months.

High-dose corticosteroids — usually intravenous methylprednisolone followed by oral prednisolone — form the backbone of induction therapy for class III and IV lupus nephritis. They rapidly suppress glomerular inflammation. However, corticosteroids alone are insufficient for most patients. Therefore, they are combined with either mycophenolate mofetil — an immunosuppressive drug that blocks immune cell proliferation — or low-dose cyclophosphamide — a stronger immunosuppressive agent used for more severe disease.

Mycophenolate mofetil is now the preferred induction agent in most international guidelines because it achieves equivalent remission rates to cyclophosphamide with a significantly better side effect profile — particularly regarding fertility preservation, which is important for the predominantly young female population affected by lupus nephritis. Furthermore, belimumab — a targeted biological therapy that reduces B cell activity — has recently demonstrated additional kidney-protective benefits when added to standard induction therapy in clinical trials. Consequently, belimumab is now approved as an add-on therapy for active lupus nephritis in several countries.

Voclosporin — a next-generation calcineurin inhibitor — has also shown significant benefit in reducing proteinuria when added to mycophenolate mofetil and low-dose corticosteroids in induction therapy. Moreover, the combination of voclosporin plus mycophenolate mofetil has become a recognised treatment option in recent lupus nephritis guidelines.

Maintenance Therapy

Maintenance therapy aims to sustain the remission achieved during induction and prevent relapse over the long term. It typically continues for at least three years after achieving complete remission. Mycophenolate mofetil at a reduced dose is the preferred maintenance agent for most patients. Azathioprine — another immunosuppressive drug — is an alternative, particularly for patients planning pregnancy because mycophenolate mofetil is harmful to a developing baby.

Hydroxychloroquine — an antimalarial drug — is recommended for all patients with lupus, including those with lupus nephritis, regardless of disease activity. It reduces lupus flare frequency, protects against organ damage, and improves long-term survival. Furthermore, it reduces the risk of lupus nephritis relapse during maintenance. Consequently, hydroxychloroquine should continue indefinitely in all patients with lupus unless a specific contraindication exists.

Supportive Treatment

Supportive treatment runs alongside immunosuppressive therapy throughout all phases of lupus nephritis management. ACE inhibitors and ARBs reduce proteinuria and protect kidney function independently of their blood pressure effects. They are recommended for all patients with lupus nephritis who have proteinuria, regardless of blood pressure level.

Tight blood pressure control — targeting below 130 millimetres of mercury systolic — slows the progression of kidney scarring. Moreover, SGLT2 inhibitors have demonstrated kidney-protective benefits in proteinuric kidney disease and are increasingly used in lupus nephritis alongside standard immunosuppressive therapy. In addition, statin therapy addresses the elevated cardiovascular risk that accompanies chronic kidney inflammation and nephrotic syndrome. Bone protection with calcium, vitamin D, and bisphosphonates is important for patients receiving prolonged corticosteroid treatment.

Living Well With Lupus Nephritis

Monitoring and Relapse Prevention

Lupus nephritis requires lifelong monitoring because relapses can occur at any time — even years after achieving complete remission. Regular check-ups measure urine protein, kidney function, blood pressure, anti-dsDNA antibodies, and complement levels. Consequently, rising anti-dsDNA levels or falling complement levels can signal an impending flare before symptoms develop, allowing doctors to intensify treatment preemptively.

Patients play an active role in monitoring their own condition. Urine dipstick testing at home allows early detection of returning proteinuria. Regular blood pressure checks identify emerging hypertension. Moreover, recognising the systemic symptoms of a lupus flare — increasing fatigue, new rash, worsening joint pain — prompts early contact with the medical team before kidney damage escalates.

Pregnancy and Lupus Nephritis

Pregnancy in people with lupus nephritis requires careful specialist planning and management throughout. Active lupus nephritis significantly increases the risks of pregnancy complications — including preeclampsia, preterm birth, and foetal growth restriction. Consequently, doctors strongly advise achieving stable remission for at least six months before attempting to conceive.

Medication safety in pregnancy is a critical concern. Mycophenolate mofetil is harmful to a developing baby and must be switched to azathioprine before conception. Hydroxychloroquine, however, is safe in pregnancy and should continue throughout. Furthermore, close collaboration between nephrology, rheumatology, and obstetric teams is essential throughout pregnancy and the postpartum period. Postpartum lupus flares are common, and kidney monitoring must continue intensively after delivery.

Lifestyle and Cardiovascular Protection

People with lupus nephritis face a significantly elevated risk of cardiovascular disease — driven by chronic inflammation, nephrotic syndrome, high blood pressure, corticosteroid use, and the disease itself. Therefore, cardiovascular risk management is as important as kidney-specific treatment in the long-term care of lupus nephritis.

Sun protection is important for all people with lupus because ultraviolet light triggers lupus flares. Daily sunscreen use, protective clothing, and avoiding peak sun exposure help reduce flare frequency. Regular moderate exercise supports cardiovascular health, helps manage weight, and improves psychological wellbeing. Furthermore, smoking cessation is essential because smoking worsens both lupus activity and cardiovascular risk simultaneously. For context on how advanced kidney disease affects multiple body systems and how kidney disease progression is staged, see our articles on focal segmental glomerulosclerosis and kidney failure.

When to Seek Urgent Medical Help

Seek emergency care immediately if you develop sudden and severe swelling, a dramatic drop in urine output, rapidly rising blood pressure, visible blood in the urine, or sudden confusion. These symptoms may signal severe active lupus nephritis, rapidly progressive kidney failure, or a dangerous hypertensive crisis — all of which require immediate hospital assessment.

Furthermore, any person with known lupus who develops new urinary symptoms — foamy urine, blood in the urine, or significantly reduced urine output — alongside worsening systemic lupus symptoms should seek urgent medical review without waiting for a routine appointment. Consequently, acting early during a lupus nephritis flare significantly reduces the risk of irreversible kidney damage.

Frequently Asked Questions

1. How common is lupus nephritis in people with lupus?

Lupus nephritis affects roughly 40 to 60% of all people diagnosed with systemic lupus erythematosus at some point during their lives. Furthermore, it tends to develop within the first five years of the lupus diagnosis in most patients. Consequently, all people with lupus need regular urine and kidney function monitoring — even when they feel well — to detect kidney involvement before symptoms appear.

2. Can lupus nephritis be cured?

There is currently no cure for lupus nephritis. However, modern treatment achieves complete remission — the absence of active kidney inflammation — in a significant proportion of patients. Furthermore, patients who achieve and maintain complete remission have kidney survival rates approaching those of the general population. Consequently, the goal of treatment is not cure but sustained remission that prevents further kidney damage over a lifetime.

3. What is the difference between lupus nephritis and other causes of kidney disease?

Lupus nephritis is specifically caused by the systemic autoimmune disease lupus. It produces a characteristic pattern of immune complex deposits in the kidneys that is distinct from other glomerular diseases such as IgA nephropathy, membranous nephropathy, or FSGS. Furthermore, lupus nephritis almost always occurs alongside other features of systemic lupus — such as rash, joint pain, and abnormal blood tests — which are not present in other kidney diseases. Consequently, the diagnosis requires both kidney biopsy findings and evidence of systemic lupus activity.

4. Does lupus nephritis always lead to kidney failure?

No. With early diagnosis and effective treatment, many patients with lupus nephritis maintain normal or near-normal kidney function for decades. However, patients with class IV disease, repeated flares, or inadequate treatment response face a significantly higher risk of progression to kidney failure. Consequently, achieving and maintaining complete remission as early as possible is the most powerful factor in preventing kidney failure.

5. Is lupus nephritis more common in certain groups of people?

Yes. Lupus itself disproportionately affects women — particularly women of childbearing age — and is more common and more severe in people of African, Hispanic, and Asian descent compared with white European populations. Furthermore, lupus nephritis tends to present at a younger age and follow a more aggressive course in people of African descent. Consequently, these groups require particularly vigilant kidney monitoring and early aggressive treatment at diagnosis.

References

1. Lupus is a chronic autoimmune disease where the body’s immune system attacks multiple organs and systems, causing inflammation and tissue damage. 
2. Lupus causes a wide variety of symptoms affecting multiple organ systems. 
3. Mixed Connective Tissue Disease has certain distinctive clinical and laboratory features that help differentiate it from other connective tissue diseases. 
4. To promote kidney health, experts recommend focusing on whole, nutrient-rich foods. 
5. Antiphospholipid Syndrome causes variable symptoms depending on whether thrombotic events have occurred and whether pregnancy is involved. Many people with antibodies are asymptomatic. 

Disclaimer

This article adapts publicly available information from WHO’s Lupus page. This content is for informational and educational purposes only and does not constitute medical advice. ObserverVoice.com is a news and information platform and not a healthcare provider.